Direct Analytical Sample Quality Assessment (DASQ) for Biomarker Investigation: Qualifying CSF Samples

Decent Essays

Cerebrospinal fluid (CSF) surrounds the brain and spinal column and contains small molecules, peptides, proteins etc., which play critical roles in many physiological processes in the central nervous system (CNS). CSF is considered a prime reservoir for neurological studies because the content of proteins and metabolites and the changes in their concentrations directly reflect the internal milieu of the brain: it offers a unique window to search for new biomarkers and to improve early diagnosis of neurological diseases [1-3]. However, the complexities of the brain and human neurological disorders represent a severe roadblock to identify novel neurological biomarkers. A biomarker can be defined as a biochemical, pharmacological or …show more content…

HUPO promotes proteomics study through international collaborations to better understand various aspects of human well-being by supporting related research into plants, livestock and pathogens. The general goal of the Biology/Disease branch of the Human Protein Project (B/D-HPP), initiated by the Human Proteome Organization, is to explore the impact that proteomic approach, exemplified by mass spectrometry technologies, can have when applied to a focused area of biology, in collaboration with specific experts in that particular field.
The B/D-HPP consortium is currently in development to form groups which collaborate on proteomics studies based on the analysis of human cells, tissues or body fluids to investigate biological networks and pathways [4].
Biobanks are often built around limited number of well assessed robust workflows often depending on a single institutional clinical cohort. For this reason such biobanks could find itself unable to meet the demands of a large international sampling programmes with different projects data and research outcomes, thus possibly generating a number of confounding conditions. In addition, the structures involved in biospecimen collection and processing are not uniform across disease's studies, and researchers who seek specific biospecimens to some diseases have not currently helped by existing biobanks. Moreover, to date, there has not been a strong linkage between clinical trials. In particular, large collection campaigns on the

Get Access